Search Results for: 19

ROCKVILLE, Md., Jan. 2, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steven Shallcross, Interim CEO & CFO, is scheduled to present at the Biotech Showcase™ 2018 Conference next week in San Francisco, as […]

ROCKVILLE, Md., Dec. 5, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steve Shallcross, the Company’s Chief Financial Officer, has been named interim CEO to succeed Jeff Riley, who has resigned as an

— Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for SYN-004 (ribaxamase) — — Conference Call Today, November 1, 2017, at 4:30 p.m. EDT — ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners,

— SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI — — Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 — — Conference Call Today, August 3, 2017, at 8:30 a.m. EDT — ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

— Conference Call Scheduled for Thursday, August 3, 2017 at 8:30 a.m. EDT — ROCKVILLE, Md., July 27, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights

— Allowance of Patent Provides Exclusive Method of Use Protection Until at Least 2034 — ROCKVILLE, Md., June 27, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office

— FDA Action Marks First Breakthrough Therapy Designation for Clinical Program Designed to Prevent Primary Clostridium difficile Infection — — Type-B Meeting Anticipated to Discuss Potential for Expedited Drug Development Strategy — ROCKVILLE, Md., May 11, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to

— Results from Phase 2b Proof-of-Concept Study Exploratory Endpoints Demonstrate Ribaxamase Protects and Preserves Gut Microbiome from Ceftriaxone-mediated Dysbiosis — — Two Ribaxamase and Two SYN-010 Presentations to be Included at Digestive Disease Week (DDW 2017) — — Conference Call Today, May 4, 2017, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 4, 2017 /PRNewswire/

— Conference Call Scheduled for Thursday, May 4, 2017 at 4:30 p.m. EDT — ROCKVILLE, Md., April, 26, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational